Ipamorelin: One Clean Knock on a Pituitary Door

The short version

Ipamorelin is a synthetic five-amino-acid peptide (a pentapeptide) designed to knock on the same receptor the stomach hormone ghrelin uses — the ghrelin receptor, also called GHS-R1a — on cells in the pituitary gland. When it binds, the pituitary releases a pulse of growth hormone (GH). What makes it distinctive among growth-hormone-releasing peptides is selectivity: unlike older compounds in its class, it does this without meaningfully raising cortisol or prolactin, hormones tied to stress and lactation.

It has never been approved as a drug anywhere. Its only published Phase 2 human trial, testing it for bowel recovery after surgery, missed its primary goal ^[10]. Most of what is known about ipamorelin comes from rodent and cell studies, plus one small human pharmacokinetics study from 1999 ^[11]. This page reports exactly what those studies found and does not extrapolate beyond them; it recommends no dose and describes no purchase pathway.

What it is

Ipamorelin's sequence — Aib-His-D-2-Nal-D-Phe-Lys-NH2 — was derived by removing two amino acids from an earlier growth-hormone-releasing peptide, GHRP-1. The remaining building blocks include a non-standard amino acid (Aib) and two D-amino acids (mirror-image versions of the ones the body normally uses), which resist the enzymes that would otherwise break the peptide down quickly. As a messenger, it is built to be selective rather than broad: it was designed specifically to activate GHS-R1a, the ghrelin receptor, without the off-target hormone effects seen in less selective molecules of its era.

How it works

Ipamorelin binds GHS-R1a on somatotrophs, the pituitary cells that store and release growth hormone, and triggers a discrete GH pulse — in one human pharmacokinetic study, that pulse peaked about 40 minutes after dosing ^[11]. Because it acts through a different receptor pathway than growth-hormone-releasing hormone (GHRH) itself, researchers have studied combining it with GHRH analogues on the theory that the two signals are complementary rather than redundant.

The same receptor also sits on enteric and vagal nerve cells (relevant to gut motility, which is why it was tested after bowel surgery), on pancreatic islet cells, and in hypothalamic appetite circuitry — a class-level property of ghrelin-receptor agonists that is not unique to ipamorelin and is discussed under safety below.

What the research shows

The defining human trial. The only published Phase 2 randomized controlled trial of ipamorelin enrolled 114 adults recovering from bowel resection surgery, dosed intravenously twice daily for up to seven days. It missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance (p=0.15). Treatment-emergent adverse events were actually less frequent in the ipamorelin group than placebo (87.5% vs 94.8%) ^[10].

Human pharmacokinetics. A small dosing study in eight healthy male volunteers per dose level found dose-proportional kinetics, a terminal half-life of roughly two hours, and a single discrete GH pulse peaking about 40 minutes after a short intravenous infusion ^[11].

Recent preclinical work. A 2024 ferret study found ipamorelin reduced chemotherapy-associated weight loss by about 24% during the delayed post-treatment phase but, unlike a related compound tested in the same study, had no effect on nausea or vomiting ^[8].

Bone growth in rats. Fifteen days of subcutaneous dosing in adult female rats increased longitudinal bone-growth rate in a dose-dependent way, without a measurable change in circulating IGF-1 — suggesting a partly local, GH-pulse-driven skeletal effect rather than a purely systemic one ^[12].

The safety anchor. No cardiovascular safety study of ipamorelin itself exists, but a 28-day study of a related ghrelin-receptor agonist in the same drug class found dose-dependent heart-muscle damage in rats after chronic oral dosing — a class-level signal, not a finding about ipamorelin directly, but the reason chronic dosing of any GHS-R1a agonist warrants caution ^[9].

Reported effects, cautions & safety

Anecdotal, not clinical evidence — the reports below come from research-use community threads, not controlled trials, and no source or dose behind them is verified.

The most consistently described benefit is deeper, more restorative sleep, often noticed within one to two weeks of a pre-bed protocol, sometimes accompanied by unusually vivid dreams in the early weeks that settle down over time. Users also frequently describe faster recovery and less soreness after training, and some report a gradual shift toward a leaner appearance over several months — though that is easily confounded by concurrent diet and exercise changes.

On the adverse side, a warm flush across the face and neck shortly after injection — often compared to a niacin flush — is widely reported and interpreted in community threads as a sign the compound is active. Tingling in the hands and feet, mild puffiness, a temporary uptick in appetite (unsurprising given the ghrelin-receptor mechanism), injection-site irritation, and occasional dizziness or a "spacey" feeling are also described. Some long-term users report the sleep and other effects fading after three to four months, which is part of why cycling protocols are commonly discussed in these communities.

Cited safety cautions, all grounded in mechanism and preclinical data rather than observed ipamorelin-specific human events: growth hormone raises IGF-1, a known mitogen, making active or recent malignancy a theoretical concern with no ipamorelin-specific tumor data to confirm or rule it out ^[8]. Ipamorelin has a direct, GH-independent insulin-releasing effect on pancreatic tissue in animal studies, creating unpredictable glycemic effects for anyone with diabetes or insulin resistance ^[8]. A related receptor-class compound produced heart-muscle damage in a 28-day rat study, making chronic dosing a concern for anyone with cardiovascular vulnerability ^[9]. The ghrelin-receptor mechanism itself is orexigenic (appetite-stimulating) and, in mice, increased fat deposition independent of growth hormone — relevant to anyone managing weight or metabolic conditions ^[9]. Beyond the single short Phase 2 trial and one small acute-dosing study, no long-term human safety data exist, and research-grade material from unregulated suppliers carries no pharmaceutical purity assurance ^[10][11]. On the positive side of the ledger, ipamorelin's defining pharmacological trait — unlike older secretagogues — is that it does not meaningfully raise cortisol or prolactin even at high doses in animal studies, a selectivity advantage specific to this compound ^[11].

Where it fits among the messengers

Ipamorelin is a narrow, selective signal — one receptor, one pituitary cell type, one hormone pulse — in contrast to semaglutide, whose GLP-1 signal reaches receptors scattered across the pancreas, stomach, and brain. It also carries by far the thinnest human evidence base on this desk: a single Phase 2 trial that did not meet its primary endpoint, and one small acute pharmacokinetics study. See how that evidence maturity compares across all five compounds on the comparison page.